Alluvi, previously BI 4744, represents a significant breakthrough in weight loss care. This dual stimulator targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling effectiveness in research https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/